Daicel Corporation (TYO:4202)

Market Cap	360.70B
Revenue (ttm)	573.96B
Net Income (ttm)	36.23B
Shares Out	262.61M
EPS (ttm)	135.50
PE Ratio	10.14
Forward PE	7.52
Dividend	60.00 (4.48%)
Ex-Dividend Date	Mar 30, 2026

Volume	884,600
Average Volume	920,015
Open	1,360.00
Previous Close	1,340.50
Day's Range	1,355.00 - 1,376.00
52-Week Range	1,057.50 - 1,420.00
Beta	0.26
RSI	67.92
Earnings Date	Feb 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In 2024, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.